Chembio Diagnostics develops, manufactures and markets rapid, point-of-care tests for the detection of HIV 1/ 2, Chagas and Sickle Cell disease as well as other human and veterinary infectious diseases, including tuberculosis (TB). Many of the company’s current products are based upon single path lateral flow technology platforms using proprietary and/or in- licensed technology. Chembio’s patented Dual Path Platform (DPP) is being employed to develop several new point-of-care products in collaboration with other companies.